OS
Fig. 3 · Panel Altered_KRAS_mutations_amplifications
Panel Altered_KRAS_mutations_amplifications 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Kohei Shitara, Yelena Y Janjigian, Jaffer Ajani, Markus Moehler, Jin Yao, Xuya Wang, Aparna Chhibber, Dimple Pandya, Lin Shen, Marcelo Garrido, Carlos Gallardo, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Bragagnoli, Tianshu Liu, Michael Schenker, Patricio Yañez, Ruben Kowalyszyn, Michalis Karamouzis, Thomas Zander, Kynan Feeney, Elena Elimova, Parul Doshi, Mingshun Li, Ming Lei
Nat Med 31(5) 1519-1530
First-line nivolumab-plus-chemotherapy demonstrated superior overall survival (OS) and progression-free survival versus chemotherapy for advanced gastroesophageal adenocarcinoma with programmed death ligand 1 combined positive score ≥ 5, meeting both primary end points of the randomized phase 3 CheckMate 649 trial. Nivolumab-plus-ipilimumab provided durable responses and higher survival rates versus chemotherapy; however, the prespecified OS significance boundary was not met. To identify biomarkers predictive of differential efficacy outcomes, post hoc exploratory analyses were performed using whole-exome sequencing and RNA sequencing. Nivolumab-based therapies demonstrated improved efficacy versus chemotherapy in hypermutated and, to a lesser degree, Epstein-Barr virus-positive tumors compared with chromosomally unstable and genomically stable tumors. Within the KRAS-altered subgroup, only patients treated with nivolumab-plus-chemotherapy demonstrated improved OS benefit versus chemotherapy. Low stroma gene expression signature scores were associated with OS benefit with nivolumab-based regimens; high regulatory T cell signatures were associated with OS benefit only with nivolumab-plus-ipilimumab. Our analyses suggest that distinct and overlapping pathways contribute to the efficacy of nivolumab-based regimens in gastroesophageal adenocarcinoma.
3 个 Figure · 14 个 KM 面板
Efficacy by KRAS alterations in patients treated with nivolumab-plus-chemotherapy versus chemotherapy. a , Kaplan–Meier estimates of OS in all WES-evaluable patients with altered (left) or unaltered (right) KRAS mutations + amplifications. b , OS by baseline KRAS pathway alteration status derived from the model, including interaction of KRAS alteration status with treatment, MSI and TMB status. Data are presented as unstratified HRs and 95% CI. c , KRAS mutation map. a MSI status not evaluable/available in two patients. KRAS , Kirsten rat sarcoma viral oncogene.
Fig. 3 · Panel Altered_KRAS_mutations_amplifications
Panel Altered_KRAS_mutations_amplifications 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 3 · Panel Unaltered_KRAS_mutations_amplifications
Panel Unaltered_KRAS_mutations_amplifications 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
OS by GES scores and PD-L1 CPS status in patients treated with nivolumab-plus-chemotherapy versus chemotherapy. a , Forest plot showing the correlation between OS and selected signatures used to stratify patients into tertiles (high, medium, or low). Data are presented as unstratified HRs and 95% CI. HR was not calculated if the number of patients in each arm was less than 5. b and c , Kaplan–Meier estimates of OS in all RNA-seq-evaluable patients with low, medium or high angiogenesis GES scores (5-gene angiogenesis) and PD-L1 CPS ≥ 5 ( b ) or PD-L1 CPS < 5 ( c ) at baseline. Chemo, chemotherapy; CI, confidence interval; CPS, combined positive score; GES, gene expression signature; HR, hazard ratio; NIVO, nivolumab; OS, overall survival; PD-L1, programmed death ligand 1.
Extended Data Fig. 5 · Panel B
Panel B 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel B_2
Panel B_2 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel B_3
Panel B_3 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel C
Panel C 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel C_5
Panel C_5 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 5 · Panel C_6
Panel C_6 是同一 Extended Data Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
OS by PD-L1 CPS and Treg status in patients treated with nivolumab-plus-ipilimumab versus chemotherapy. a and b , Kaplan–Meier estimates of OS in all RNA-seq-evaluable patients with high, medium or low regulatory T cell GES scores (2-gene regulatory T cell) and PD-L1 CPS ≥ 5 ( a ) or PD-L1 CPS < 5 ( b ) at baseline. Chemo, chemotherapy; CI, confidence interval; CPS, combined positive score; HR, hazard ratio; IPI, ipilimumab; NIVO, nivolumab; OS, overall survival; PD-L1, programmed death ligand 1.
Extended Data Fig. 7 · Panel Treg-high_a_
Panel Treg-high_a_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel Treg-high_b_
Panel Treg-high_b_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel Treg-medium_a_
Panel Treg-medium_a_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel Treg-medium_b_
Panel Treg-medium_b_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel Treg-low_a_
Panel Treg-low_a_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Extended Data Fig. 7 · Panel Treg-low_b_
Panel Treg-low_b_ 是同一 Extended Data Fig. 7 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。